These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35963646)

  • 1. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.
    Yang W; Han B; Chen Y; Geng F
    Aging (Albany NY); 2022 Aug; 14(15):6316-6337. PubMed ID: 35963646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma.
    Tong S; Jiang N; Wan JH; Chen CR; Wang SH; Wu CY; Guo Q; Xiao XY; Huang H; Zhou T
    BMC Cancer; 2023 Mar; 23(1):275. PubMed ID: 36973678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
    Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
    Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis of
    Wang X; Tang Y; Liu R; Li W; Liu S; Zhou X
    Biotechnol Genet Eng Rev; 2024 Nov; 40(3):1591-1613. PubMed ID: 36989393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.
    Qu J; Sun F; Hou Y; Qi H; Sun X; Xing L
    BMC Cancer; 2023 Jun; 23(1):549. PubMed ID: 37322434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
    Front Immunol; 2022; 13():951247. PubMed ID: 35935945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
    Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
    Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of PHF5A as a potential prognostic biomarker and therapeutic target across cancers and in hepatocellular carcinoma.
    Cheng Q; Ji W; Lv Z; Wang W; Xu Z; Chen S; Zhang W; Shao Y; Liu J; Yang Y
    BMC Cancer; 2024 Jul; 24(1):868. PubMed ID: 39030507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.
    Liu C; Qu Z; Zhao H; Wang P; Zhan C; Zhang Y
    BMC Bioinformatics; 2023 May; 24(1):192. PubMed ID: 37170221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 14. A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint.
    Lu H; Liang J; He X; Ye H; Ruan C; Shao H; Zhang R; Li Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value and immunological role of PD-L1 gene in pan-cancer.
    Wang Y; Jiang H; Fu L; Guan L; Yang J; Ren J; Liu F; Li X; Ma X; Li Y; Cai H
    BMC Cancer; 2024 Jan; 24(1):20. PubMed ID: 38166842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
    Ma P; Sun W
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.